Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

EPS and iPS Cells in Disease Research

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

High-throughput protein target mapping enables accelerated bioactivity discovery for ToxCast and PFAS compounds.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

ABHD2 activity is not required for the non-genomic action of progesterone on human sperm.

Human reproduction (Oxford, England)·2026

Same author

High-affinity, structure-validated and selective macrocyclic peptide tools for chemical biology studies of Huntingtin.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Novel monoclonal antibodies against the C-terminal HEAT domain of huntingtin.

Journal of Huntington's disease·2026

Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same journal

HuR degrader knocks down BRAF in cancer.

Nature reviews. Drug discovery·2026

Same journal

R&D productivity trends for biopharma companies in Asia and emerging markets.

Nature reviews. Drug discovery·2026

Same journal

Growth in clinical research capability in China and impact on the pharmaceutical sector.

Nature reviews. Drug discovery·2026

Same journal

Circular RNA guides exon skipping in DMD.

Nature reviews. Drug discovery·2026

Same journal

p38α inhibition restores axonal transport.

Nature reviews. Drug discovery·2026

Same journal

Inflammatory bowel disease-on-a-chip.

Nature reviews. Drug discovery·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 16, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Preclinical target validation using patient-derived cells.

Aled M Edwards¹, Cheryl H Arrowsmith², Chas Bountra³

¹Structural Genomics Consortium, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada.

Nature Reviews. Drug Discovery

|February 28, 2015

Summary

This summary is machine-generated.

The Structural Genomics Consortium is launching open-source preclinical studies. These translational medicine initiatives involve clinical, industry, and disease-foundation partners.

More Related Videos

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Published on: March 13, 2013

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Experiment Videos

Last Updated: Apr 16, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Published on: March 13, 2013

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Area of Science:

Biomedical Research
Translational Medicine
Drug Discovery

Background:

The Structural Genomics Consortium (SGC) facilitates research collaborations.
Preclinical research is crucial for advancing medical treatments.
Open-source approaches can accelerate scientific progress.

Purpose of the Study:

To launch novel open-source preclinical translational medicine studies.
To foster collaboration between academic, industry, and disease-foundation partners.
To accelerate the development of new therapies.

Main Methods:

Establishing collaborative research frameworks.
Implementing open-source data sharing protocols.
Coordinating preclinical study designs.

Main Results:

Initiation of multiple open-source preclinical studies.
Formation of a multi-sector consortium.
Development of shared research resources.

Conclusions:

Open-source preclinical studies can enhance translational medicine.
Partnerships across sectors are vital for drug development.
The SGC model promotes collaborative scientific advancement.